J Rheumatol: The efficacy of continuous and intermittent ceresibu treatment of osteoarthritis

The purpose of this study was to determine whether "continuous" ceresib was more effective than "intermittent" in preventing knee and/or hip osteoarthritis (OA) flaresa double-blind, randomized, multicenter international study that included 858 OA patients aged 18-80 who received 200 mg/day of continuous (daily) and intermittent (based on predetermined OA flare) treatment, comparing the effectiveness and safety of the two groupsThe study consisted of three phases: (I) screening/observation period; (II) open labeling trial sereibu; and (III) 22-week double-blind treatmentOnly subjects with stage 2 OA flares that faded (no subsequent flares) were randomly groupedThe main endpoint was compared using anovaisive analysis (with treatment as an argument), i.ethe number of flares exposed per time during phase III (the number of flares per month)Acetaminophen can be used as an emergency medicineresults showed that 858 of the 875 randomly treated subjects received treatmentIn the randomized group, 70 per cent were women; the average age was 58.6 years; the average course of the disease was 6.5 years; the total osteoarthritis index at Western Ontario and McMaster University averaged 25.8; about 45 per cent had high blood pressure; and about 20 per cent of people used aspirin (for cardiovascular prevention)Subjects receiving continuous treatment reported a 42% reduction in OA recurrence/month compared to intermittent users (P 0.0001) or 2.0 oA recurrence within 22 weeksStatistical and clinical of minor efficacy in ongoing treatment? The benefits are also clearThere is no difference in adverse events (AE) or new/aggravated hypertension, the results showed that continuous use of 200 mg/day of treatment withced 200 mg/day of treatment was significantly better than intermittent use in preventing OA recurrence in the hip and knee joints without increasing the total aEs, including gastrointestinal diseases and hypertension